Investigation of improved Helicobacter pylori eradication rate using Vonoprazan for first-line therapy: large prospective study.

Investigation of improved Helicobacter pylori eradication rate using Vonoprazan for first-line therapy: large prospective study. - H. pylori eradication rate using Vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021383

Enrollment

500

Registered

2016-03-07

Start date

2016-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Vonoprazan 20mg / Vonoprazan 20mg bid Amoxicillin 750mg / Amoxicillin 750mg bid Clarithromycin 400mg / Clarithromycin 400mg bid daily for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Helicobacter pylori infection Willingness to provide informed consent.

Exclusion criteria

Exclusion criteria: Patients with gastric cancer identified by initial gastroduodenal endoscopy Patients who hava allergy to eraducation drugs Patients who have severe diseases affecting the kidney. Patients who have severe diseases affecting the heart. Patients who have severe diseases affecting the liver. Patients judged as inappropriate candidates for the trial by the investigators

Design outcomes

Primary

Measure	Time frame
Eradication rate of Helicobacter pylori	—

Secondary

Measure	Time frame
Changes of abdominal symptom (GSRS) Risk factors for the failure of Helicobacter pylori eradication (Age, Sex, smoking habit, drinking habit, obesity, past history, medication)	—

Countries

Japan

Contacts

Public ContactYoshitsugu Misumi

NTT Medical Center Tokyo Gastroenterology

yoshikft34@gmai.com03-3448-6547

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026